adavosertib

Adavosertib is a first-in-class, selective, small-molecule inhibitor of the tyrosine kinase WEE1. By inhibiting WEE1, adavosertib disrupts the G2 DNA damage checkpoint in cancer cells, particularly those with p53 deficiencies. This abrogation leads to premature mitosis and cell death in tumor cells that rely on this checkpoint for survival after DNA damage. Adavosertib has demonstrated antitumor activity as monotherapy and in combination with other agents across various solid tumors, including ovarian cancer (notably *CCNE1*-amplified), triple-negative breast cancer, small-cell lung cancer, and other refractory solid tumors. The drug was originally developed by Merck & Co and further developed by AstraZeneca and several academic collaborators[3][6][8].

Brand names

adavosertib

Other names

adavosertibum